Celldex Therapeutics Unveils Exciting Results
Celldex Therapeutics, Inc. has announced that an abstract featuring 52-week results from its Phase 2 clinical trial of barzolvolimab—targeting patients with chronic spontaneous urticaria (CSU)—will be presented during a late-breaking oral session. This presentation is scheduled to take place at the 2024 European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam.
Details About the Presentation
This significant announcement underscores Celldex's continued dedication to solving pressing issues faced by CSU patients, particularly those who don't find relief with standard antihistamine treatments. The session on Wednesday is expected to engage attendees with the latest developments in dermatology and allergy management.
The abstract to be shared at the conference will highlight the impressive efficacy and safety profile of barzolvolimab, observed throughout the 52-week trial. This marks an important advance for individuals who suffer from severe symptoms that existing therapies fail to address.
Presentation Highlights
Here are key details about the upcoming presentation:
- Abstract Title: Barzolvolimab shows profound efficacy and favorable safety over 52 weeks in patients with Chronic Spontaneous Urticaria
- Presenting Author: Martin Metz, M.D., a highly respected professor specializing in dermatology and allergy
- Session: D1T01.2: Late breaking news
- Date/Time: Wednesday, September 25 at 16:45-17:00 CEST (10:45 – 11:00 am ET)
Introduction of E-Poster
Alongside the oral presentation, Celldex will also showcase an e-Poster (#P3596) titled "Barzolvolimab treatment improves quality of life and urticaria control in patients with chronic spontaneous urticaria (CSU): Results from a Phase 2 trial." This e-Poster aims to provide insights into how patients managed their symptoms and enhanced their quality of life after undergoing treatment.
Importance of Barzolvolimab
Barzolvolimab, known as CDX-0159, represents an innovative strategy for addressing CSU by focusing on mast cell biology. This approach holds the potential to transform treatment pathways for individuals grappling with chronic allergies, autoimmune issues, and other serious inflammatory conditions. Moreover, the emphasis on safety throughout the extensive trial reflects Celldex's strong commitment to ensuring patient safety and well-being.
About Celldex Therapeutics
Celldex Therapeutics is an innovative clinical-stage biotechnology company that is committed to developing therapies that work harmoniously with the human immune system. The company focuses on creating antibody-based therapeutics that effectively influence vital immune response pathways, bringing hope to those suffering from severe allergies and autoimmune diseases.
Dedication to Progress
Celldex exemplifies innovation through its diverse pipeline of potential therapeutic candidates. Their ongoing commitment to improving therapeutic effectiveness demonstrates a proactive stance in the biotechnology landscape.
Contact Information for the Company
If you have any questions, please reach out to:
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com
Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com
Frequently Asked Questions
What will Celldex present at the upcoming event?
Celldex will present the findings from a Phase 2 trial for barzolvolimab, focusing on chronic spontaneous urticaria.
Where can people attend the EADV Congress?
The EADV Congress will be hosted in Amsterdam.
What do the trial results say about barzolvolimab?
The trial findings indicate that barzolvolimab demonstrates significant efficacy and possesses a favorable safety profile for treating chronic spontaneous urticaria.
Who will be presenting the results?
The results will be shared by Martin Metz, M.D., a distinguished expert in dermatology and allergy.
How can I get more information about Celldex Therapeutics?
You can find additional information on their official website or by contacting the company through their provided email addresses.
